Scientists at the University of Sydney have uncovered a malfunctioning version of the SOD1 protein that clumps inside brain ...

Groundbreaking research by Sydney University found a new brain protein involved in Parkinson’s disease and a way to modify it ...

A newly discovered brain protein linked to Parkinson’s offers hope for targeted therapies that could slow or prevent disease ...

Groundbreaking research by the University of Sydney has identified a new brain protein involved in the development of ...

Now, scientists at the University of Sydney have made an exciting discovery: they’ve found a new brain protein linked to ...

The disease, which is caused by mutations in the SOD1 gene, accounts for approximately 10% to 20% of genetic ALS cases and 1% to 2% of sporadic ALS cases, according to the ALS Association. 7.

The U.S. Food and Drug Administration approved a new drug Tuesday to treat a rare form of amyotrophic lateral sclerosis, or ALS.. The drug Qalsody (tofersen) is expected to help people with a very ...

The decision on the SOD1 ALS program does not impact Voyager’s other gene therapy programs; the Company continues to expect IND filings in 2025 from Neurocrine Biosciences for the program in ...

LEXINGTON, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today ...

Treatment with tofersen in patients with superoxide 1 dismutase 1 ALS was linked to preservation of motor function, maintenance of muscle strength and reduction of disease-specific biomarkers ...

DM is caused by inherited changes to a gene called superoxide dismutase 1, or SOD1. This gene gives instructions to the superoxide dismutase enzymes, which act as antioxidants and help rid the ...